Katina Dorton
Director · Keenova Therapeutics plc
Individual
- 2025
- Jul 18, 2026
- 10
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Katina Dorton files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ORBIMED ADVISORS LLC - $12.50M in PRLD purchases and sales in the last 12 months
- David P. Bonita - $12.50M in PRLD purchases and sales in the last 12 months
- BAKER BROS. ADVISORS LP - $10.00M in PRLD purchases and sales in the last 12 months
- Kevin Tang - $1.49M in FULC purchases and sales in the last 12 months
- Robert J. Gould - $507K in FULC purchases and sales in the last 12 months
- Lynx1 Capital Management LP - $146K in TCRX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Katina Dorton?
Katina Dorton is a corporate insider, tracked as Director of Fulcrum Therapeutics, Inc. (FULC). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Katina Dorton last file a Form 4?
The most recent primary Form 4 on record is dated 18 July 2026, one of 10 filings going back to 2025.
